Feifel D

Kadima Neuropsychiatry Institute, La Jolla, CA, USA; University of California, San Diego, CA, USA.

6 papers

ArticleKetamine

DATAd: A new communication and tracking system for treatment-resistant depression.

Conroy SK, Voytenko VL, Docherty AR +6

Europe PMC2026
ArticlePsilocybin

The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis.

Goodwin GM, Aaronson ST, Alvarez O +23

Europe PMC2026
ArticlePsilocybin

Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers' task group on psychedelics and related compounds.

Lewis BR, Reid MJ, Novick AM +9

Europe PMC2026
ArticlePsilocybin

Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].

Goodwin GM, Aaronson ST, Alvarez O +28

Europe PMC2026
ArticlePsilocybin

The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.

Goodwin GM, Aaronson ST, Alvarez O +28

Europe PMC2025
ArticlePsilocybin

Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.

Goodwin GM, Croal M, Feifel D +11

Europe PMC2023